Abbott Laboratories Will Not Extend CEO Robert Ford's Change-in-Control Agreement
Abbott Laboratories has decided not to extend the change-in-control agreement for CEO Robert Ford, which is set to expire in December.
Stocks · News reference
A proposed class action lawsuit alleges that Abbott Laboratories falsely advertises Glucerna nutrition shakes as containing only one gram of sugar despite the presence of allulose.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Abbott Laboratories has decided not to extend the change-in-control agreement for CEO Robert Ford, which is set to expire in December.
The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.
Abbott's new Instinct™ sensor, offering up to 15 days of wear, has been selected as a compatible sensor for the newly cleared MiniMed Fit™ tubeless insulin pump.
Filed: 2026-11-16 AccNo: 0001104659-26-127273 Size: 243 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Abbott will serve as the presenter for the inaugural CES Health Hub at the upcoming CES 2027 event, focusing on advancements in digital health and connected medical technologies.
Abenójar Tungsten, S.A. issued its first market update following its October 2026 IPO, highlighting progress at the El Moto tungsten and gold project in Spain.